Investor Relations

Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, we have an economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) (FF/UMEC/VI), the combination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) GSK961081 (‘081) and FF (‘081/FF), and MABA monotherapy.

Theravance Biopharma is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections, central nervous system (CNS)/pain and gastrointestinal (GI) motility dysfunction. By leveraging our proprietary insight of multivalency to drug discovery, we are pursuing a best-in-class strategy designed to discover superior medicines in areas of significant unmet medical need.

Theravance Biopharma, Inc. became an independent, publicly-held corporation in June 2014 in connection with its spin-off from Theravance, Inc.  Theravance Biopharma, Inc. trades on the NASDAQ Global Select Market under the symbol TBPH.

By clicking on the link below, you will leave
Form content here please :)